Mirian Vaquero-Fernandez
Heidelberg, BW 69120, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Claudin-1 targeting suppresses tumor growth, invasion, and metastasis in patient-derived cholangiocarcinoma models.
Journal: Science translational medicine
Published: June 03, 2026
Spliceosome induction is a druggable dependency of RAS-driven senescence and cancer.
Journal: Nature communications
Published: November 24, 2025
Ultra-high-scale cytometry-based cellular interaction mapping.
Journal: Nature methods
Published: March 07, 2024
Activated ATF6α is a hepatic tumour driver restricting immunosurveillance.
Journal: Nature
Published: October 05, 2023
Cytokine-armed dendritic cell progenitors for antigen-agnostic cancer immunotherapy.
Journal: Nature cancer
Published: March 17, 2023
Acute expression of human APOBEC3B in mice results in RNA editing and lethality.
Journal: Genome biology
Published: February 20, 2023
Intestinal B cells license metabolic T-cell activation in NASH microbiota/antigen-independently and contribute to fibrosis by IgA-FcR signalling.
Journal: Journal of hepatology
Published: February 02, 2023
Combined hepatocellular-cholangiocarcinoma derives from liver progenitor cells and depends on senescence and IL-6 trans-signaling.
Journal: Journal of hepatology
Published: June 16, 2022
Treatment of HCC with claudin-1-specific antibodies suppresses carcinogenic signaling and reprograms the tumor microenvironment.
Journal: Journal of hepatology
Published: February 21, 2022
A human liver cell-based system modeling a clinical prognostic liver signature for therapeutic discovery.
Journal: Nature communications
Published: July 16, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026